文献速递甲状腺疾病

综合DNA甲基化谱分析鉴定甲状腺癌的新型诊断生物标志物

Comprehensive DNA Methylation Profiling Identifies Novel Diagnostic Biomarkers for Thyroid Cancer.
PubMed 文献 · Thyroid · 2020-01-09

研究对34份新鲜冷冻甲状腺组织(非肿瘤7例、NIFTP 6例、PTC 21例)进行EPIC阵列甲基化谱分析,并在293份石蜡组织(FA 61例、HA 24例、NIFTP 56例、PTC 120例、FTC 27例、HCC 5例)中焦磷酸测序验证。三个标记可区分非恶性滤泡性病变与分化型甲状腺癌,低甲基化与复发/持续性疾病及远处转移相关。

要点

  • 三个甲基化标记区分非恶性(FA、HA、NIFTP)与分化型甲状腺癌的AUC分别为0.83、0.83、0.80。
  • 分化型甲状腺癌中三个标记低甲基化与复发或持续性疾病相关(OR=3.860,95%CI 1.194-12.475)。
  • 分化型甲状腺癌中三个标记低甲基化与远处转移相关(OR=4.009,95%CI 1.098-14.632)。

核心结论

  • 三个标记的DNA甲基化水平可用于区分分化型甲状腺癌与非恶性滤泡性甲状腺病变,并可能作为预测分化型甲状腺癌术后复发或持续性疾病的预后生物标志物。

研究设计与样本

  • 发现集对34份新鲜冷冻组织(非肿瘤7例、NIFTP 6例、PTC 21例)用Illumina HumanMethylation EPIC阵列进行甲状腺肿瘤特异性DNA甲基化谱分析。
  • 验证集对293份石蜡组织(FA 61例、HA 24例、NIFTP 56例、PTC 120例、FTC 27例、HCC 5例)用焦磷酸测序验证候选标记。

主要发现

  • 三个标记(cg10705422、cg17707274、cg26849382)区分非恶性(FA、HA、NIFTP)与分化型甲状腺癌的AUC分别为0.83、0.83、0.80。
  • 分化型甲状腺癌中三个标记低甲基化与复发或持续性疾病相关(OR=3.860,95%CI 1.194-12.475),与远处转移相关(OR=4.009,95%CI 1.098-14.632)。
  • 验证集亚组分析显示PTC患者中低甲基化者较高甲基化者更常具有侵袭性组织学、甲状腺外侵犯、淋巴结转移、BRAFV600E突变及复发或持续性疾病。
  • 所有发生疾病复发的PTC患者三个标记均为低DNA甲基化水平。

临床怎么用

  • 作者认为三个标记的DNA甲基化水平可用于区分分化型甲状腺癌与非恶性滤泡性甲状腺病变。
  • 作者认为三个标记可能作为预测分化型甲状腺癌术后复发或持续性疾病的预后生物标志物。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: There are no reliable biomarkers to accurately differentiate indolent thyroid tumors from more aggressive thyroid cancers. This study aimed to develop new DNA methylation markers for diagnosis and recurrence risk stratification of papillary thyroid carcinoma (PTC). Methods: Thyroid tumor-specific DNA methylation profiling was investigated in 34 fresh frozen tissues, which included nontumor (n = 7), noninvasive follicular thyroid neoplasms with papillary-like nuclear features (NIFTP, n = 6) and PTC (n = 21), using the Illumina HumanMethylation EPIC array. We performed a genome-wide assessment of thyroid tumor-specific differentially methylated CpG sites in the discovery set, then validated the top candidate markers in an independent set of 293 paraffin tissue samples comprised of follicular adenoma (FA, n = 61), Hürthle cell adenoma (HA, n = 24), NIFTP (n = 56), PTC (n = 120), follicular thyroid carcinoma (n = 27), and Hürthle cell carcinoma (n = 5), by pyrosequencing. Results: Three selected markers (cg10705422, cg17707274, and cg26849382) differentiated nonmalignant (FA, HA, and NIFTP) tumors from differentiated thyroid cancers with area under the receiver operating characteristic curve of 0.83, 0.83, and 0.80, respectively. Low DNA methylation levels for three markers were significantly associated with recurrent or persistent disease (odds ratio (OR) = 3.860 [95% confidence interval (CI) 1.194-12.475]) and distant metastasis (OR = 4.009 [CI 1.098-14.632]) in patients with differentiated thyroid cancer. A subgroup analysis for the validation set showed that PTC patients with low DNA methylation levels more frequently had aggressive histology, extrathyroidal extension, lymph node metastasis, BRAFV600E mutations, and recurrent or persistent disease than those with high levels of methylation markers. All PTC patients who developed disease recurrence had low DNA methylation levels for three markers. Conclusions: DNA methylation levels of three markers can be useful for differentiating differentiated thyroid cancer from nonmalignant follicular thyroid lesions, and may serve as prognostic biomarkers for predicting recurrent or persistent disease after surgery for differentiated thyroid cancer.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Park JL, Jeon S, Seo EH, et al. Comprehensive DNA Methylation Profiling Identifies Novel Diagnostic Biomarkers for Thyroid Cancer. Thyroid. 2020. PMID: 31797753. doi:10.1089/thy.2019.0011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。